Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Parenting In A Pandemic: To Vaccinate Or Not To Vaccinate?

11/27/2021 | 01:10am EST

The COVID-19 pandemic has forced co-parents to make difficult decisions about parenting schedules, social distancing, online schooling, masks, and now vaccinations. Last week, Health Canada authorized the use of the Pfizer vaccine in children aged 5 to 11. The BC Centre for Disease Control (the "BCCDC") has since recommended that parents vaccinate their children against COVID-19, noting,

"Even though severe illnesses from COVID-19 in children are not common, they can occur. Vaccinating children helps keep them safe, and helps them keep people in their family and community - especially older adults, younger children and infants, and those with illnesses - safe as well."

A co-parent that opposes the COVID-19 vaccination for their child is unlikely to garner the court's support, unless there are other medical reasons for why the child should not be vaccinated. The court's only consideration in matters involving children is the child's best interest. When it comes to children and vaccines, courts have almost universally favored permitting the vaccination of the child.

Even before a COVID-19 vaccine was approved for use in Canada, the Ontario Court of Justice in Tarkowski v. Lemieux, 2020 ONCJ 280 gave the father authority to vaccinate his 7 year old daughter against the virus, should a vaccine against COVID-19 become available. In this case, the mother was opposed to vaccines in general and initially refused to consent to the child being immunized as an infant.

Later when a vaccine became available for children aged 12 and up, the Queen's Bench for Saskatchewan in O.M.S. v. E.J.S., 2021 SKQB 243 ordered that a 12-year-old child be vaccinated against COVID-19 despite her wish not to be vaccinated and a diagnosis of "possible" vaccine toxicity. The father sought to have his daughter vaccinated, but the mother vehemently opposed it.

Both parents brought extensive medical evidence. In support of vaccination, the father brought evidence from an infectious disease physician, an assistant professor and Canada Research Chair in emerging viruses in the Department of Medical Microbiology and Infectious Diseases at the University of Manitoba, and the child's family physician from birth. In opposition, the mother brought evidence from a family physician from another province that indicated he has a special interest in vaccines and is opposed to vaccinations with the Pfizer vaccine, and an anaesthesiologiest and previous tenured professor regarding a "possible" vaccine toxicity diagnosis. While the court preferred the father's expert evidence, the court did not rely on it.

Ultimately, the court's decision rested on the facts that did not require evidence, as they were found to be "so notorious as not to be the subject of dispute among reasonable people". At paragraphs 112 to 114 the court held:

  1. Canada has been in a COVID-19 pandemic;
  2. the possibility of contracting the COVID-19 virus poses serious and significant health risk to people generally, including children and adults; and
  3. the Pfizer vaccine is safe and effective for use in people, including both adults and children.

Accordingly, the court refused to consider arguments relating to the legitimacy of the pandemic, the government's response, and the safety or efficacy of vaccines approved by Health Canada. Instead, the court considered only the best interest of the child, determined by such factors as the child's needs, views or desires.

In this case, the child's wish not to be vaccinated was considered but given little weight. The court was concerned that this view was merely influenced by others. The court rejected the argument that the child's needs were impacted by a medical diagnosis of "possible" vaccine toxicity. The physician's diagnosis was not definitive and was based on incomplete medical information. As such, the court was not satisfied that the child's health would be compromised by the vaccine.

Even without particular vulnerability to the COVID-19 virus, vaccinating the child was in the daughter's best interest because the child could contract the COVID-19 virus, it was in the child's best interest to avoid contracting the virus, and the most efficacious way to avoid contracting the COVID-19 virus at this time is through vaccination.

While BC courts have not weighed in on COVID-19 vaccines for children, they have consistently provided the pro-vaccine parent with the authority to make decisions about the vaccinating the child in accordance with Public Health Department and Health Authority recommendations. In M.J.T. v. D.M.D., 2012 BCSC 863 and G.M. v. S.S., 2012 BCSC 1491, the Supreme Court of BC authorized the father to vaccinate his unvaccinated preschooler, despite the mother's belief that pediatric vaccines contribute to autism in children. In both cases, the court preferred medical evidence that demonstrated the benefits of immunization for the child outweighed any risk of side effects.

These cases demonstrate that vaccines approved by Health Canada and recommended by health authorities will almost universally be in the best interest of a child. Now that the Pfizer vaccine is approved for younger children and the BCCDC recommends parents vaccinate their children to keep them safe, co-parents in BC should be prepared for courts to conclude that the vaccination is in the best interest of their child.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Ms Chantal Cattermole
Clark Wilson LLP
900-885 West Georgia Street
Vancouver
BC V6C 3H1
CANADA
Tel: 6046875700
Fax: 6046876314
E-mail: LLK@cwilson.com
URL: www.cwilson.com

© Mondaq Ltd, 2021 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

All news about PFIZER, INC.
04:46pPzifer, OPKO Health Evaluating FDA's Complete Response Letter on Growth Hormone Replace..
MT
04:31pPfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for ..
BU
04:17pModerna's Valuation Has Come 'Back to Earth,' Become More Reasonable, BofA Securities S..
MT
03:37pBoosters provide 'added protection' against Omicron -CDC
RE
03:30pSmall children getting less sick from Omicron; Genetic mutation protects against severe..
RE
02:56pBooster shots needed against omicron, CDC studies show
AQ
02:36pU.S. studies highlight the need for COVID boosters to fight Omicron
RE
11:56aPfizer-BioNTech's COVID-19 Vaccine Gets WHO Backing for Kids 5 to 11 Years Old
MT
11:39aGlaxo Unit Valuation Boost Looks Less Likely as Unilever Walks -- Market Insight
DJ
11:19aPfizer's COVID-19 Vaccine Gets WHO Backing for Kids Ages 5 to 11
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 972 M - -
Net income 2021 22 216 M - -
Net Debt 2021 27 397 M - -
P/E ratio 2021 14,2x
Yield 2021 2,93%
Capitalization 303 B 303 B -
EV / Sales 2021 4,04x
EV / Sales 2022 3,19x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 54,05 $
Average target price 57,79 $
Spread / Average Target 6,91%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Susan Silbermann President & General Manager-Pfizer Vaccines
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-8.47%303 375
JOHNSON & JOHNSON-3.40%435 037
ROCHE HOLDING AG-3.69%322 260
ABBVIE INC.-1.75%235 181
NOVO NORDISK A/S-13.40%220 833
ELI LILLY AND COMPANY-11.98%220 420